All In Biotech

BLA 125544 · Celltrion INC

Inflectra

Infliximab-Dyyb · Injection · Tumor Necrosis Factor Blocker

Last checked: Nov 20, 2026Latest source record: Sep 3, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2016

Apr 5, 2016

Approved uses

2

Original approval plus efficacy supplements

Registered trials

379

125 Phase 3, 45 recruiting

FAERS reports

29,668

24,848 serious, 722 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SERIOUS INFECTIONS and MALIGNANCY WARNING: SERIOUS INFECTIONS and MALIGNANCY See full prescribing information for complete boxed warning • Increased risk of serious infections leading to hospitalization or death, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis) and infections due to other opportunistic pathogens. ( 5.1 ) • Discontinue INFLECTRA if a patient develops a serious infection. • Perform test for latent TB; if positive, start treatment for TB prior to starting INFLECTRA. Monitor all patients for active TB during treatment, even if initial latent TB test is negative. ( 5.1 ) • Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with tumor necrosis factor (TNF) blockers, including infliximab products. ( 5.2 ) • Postmarketing cases of fatal hepatosplenic T-cell...

What it is approved for

From the label in effect Oct 29, 2026.

INFLECTRA is a tumor necrosis factor (TNF) blocker indicated for: Crohn's Disease ( 1.1 ): • reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. • reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing disease. Pediatric Crohn's Disease ( 1.2 ): • reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active disease who have had an inadequate response to conventional therapy. Ulcerative Colitis ( 1.3 ): • reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. Pediatric Ulcerative Colitis ( 1.4 ): • reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active disease who have had an inadequate response to conventional therapy. Rheumatoid Arthritis ( 1.5 ) in combination with methotrexate: • reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active disease. Ankylosing Spondylitis ( 1.6 ): • reducing signs and symptoms in adult patients with active disease. Psoriatic Arthritis ( 1.7 ): • reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function in adult patients. Plaque Psoriasis ( 1.8 ):...

Mechanism: Infliximab products neutralize the biological activity of TNFα by binding with high affinity to the soluble and transmembrane forms of TNFα and inhibit binding of TNFα with its receptors. Infliximab products do not neutralize TNFβ (lymphotoxin-α), a related cytokine that utilizes the same receptors as TNFα. Biological activities attributed to TNFα include: induction of proinflammatory cytokines such as interleukins (IL) 1 and 6, enhancement of leukocyte migration by increasing endothelial layer permeability and expression of adhesion molecules by endothelial cells and leukocytes, activation...

Therapeutic areas: Oncology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • INFLECTRA · INFLIXIMAB-DYYB 100MG · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Infliximab" as an intervention, any sponsor and status, largest first.

All 379 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use15,555
  • condition aggravated10,827
  • intentional product use issue8,399
  • inappropriate schedule of product administration7,041
  • arthralgia5,039
  • drug ineffective3,658
  • fatigue3,494
  • weight increased3,200
  • weight decreased3,079
  • malaise2,963
  • headache2,464
  • nausea2,417

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20157
2016168
20171,138
20182,497
20191,612
20202,604
20213,484
20224,878
20234,251
20244,072
20252,706
20262,251

Recalls

1 FDA enforcement reports for this application.

  • Jan 17, 2025 · Class II · Ongoing

    cGMP Deviations: Product intended for quarantine was inadvertently distributed.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Inflectra (Infliximab-Dyyb)

2024 spending

$37.7M

Beneficiaries

1,412

7,072 claims

Per beneficiary

$26,691

$737.48 per unit

View as table
YearSpending
2020$5,625,504
2021$10,447,840
2022$23,565,720
2023$32,372,830
2024$37,687,135

Part B: Inflectra (Infliximab-Dyyb) · HCPCS Q5103

2024 spending

$21.1M

Beneficiaries

6,150

31,609 claims

Per beneficiary

$3,430

2024 ASP limit $12.42 per unit

View as table
YearSpending
2020$71,265,191
2021$71,993,955
2022$73,696,298
2023$34,946,163
2024$21,096,945

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,993 on PubMed

Sponsor: Celltrion INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.